Clinical Trials Logo

Anticoagulant clinical trials

View clinical trials related to Anticoagulant.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05788913 Not yet recruiting - Anticoagulant Clinical Trials

Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration

Start date: June 1, 2023
Phase: Phase 1
Study type: Interventional

Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/ 0.25 mL; Blau Farmacêutica S/A. Comparator Drug: Heparin Sodium Injection, USP, injectable solution - 5,000 IU/ 0.5 mL; Fresenius Kabi Lake Zurich. Evaluate the equivalence in terms of pharmacodynamics of heparin sodium (test product) and Heparin Sodium Injection, USP (comparator product). The clinical trial will last approximately 08 weeks and the study population will consist of 68 healthy research participants, 34 women and 34 men

NCT ID: NCT05788900 Not yet recruiting - Anticoagulant Clinical Trials

Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration

Start date: June 1, 2023
Phase: Phase 1
Study type: Interventional

Pharmacodynamic Study - Phase I Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/mL; Blau Farmacêutica S/A. Comparator Drug: Heparin Sodium Injection, USP, injectable solution - 5,000 IU/mL; Fresenius Kabi Lake Zurich. Evaluate the equivalence in terms of pharmacodynamics of heparin sodium (test product) and Heparin Sodium Injection, USP (comparator product). The clinical trial will last approximately 08 weeks and the study population will consist of 68 healthy research participants, 34 women and 34 men.

NCT ID: NCT04592822 Not yet recruiting - Anticoagulant Clinical Trials

A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Start date: January 6, 2021
Phase: Phase 1
Study type: Interventional

This study will be a single-center, randomized, single-dose, open-label, two-treatment, two-period, two-sequence crossover bioequivalence study to compare the rate and extent of absorption of WD-1602 granule formulation (WD Pharma) to the reference drug Pradaxa® capsule (BI, Germany) under fed conditions in healthy subjects.